NCT05584631View on ClinicalTrials.gov

IVIG Vs SCIG in CIDP

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 11, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
CIDPImmunoglobulin DeficiencyChronic Inflammatory Demyelinating Polyneuropathy
Interventions
DRUG

Intravenous immune globulin G

Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.

DRUG

Subcutaneous immune globulin G

Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.

Trial Locations (1)

08901

Rutgers, The State University of New Jersey Clinical Research Center, New Brunswick

All Listed Sponsors
lead

Rutgers, The State University of New Jersey

OTHER